Overview


According to FutureWise analysis the market for heparin in 2023 is US$ 7.62 billion, and is expected to reach US$ 9.45 billion by 2031 at a CAGR of 2.72%.

Heparin is a member of the class of medications known as anticoagulants, commonly referred to as "blood thinners." It works by reducing the ability of the blood to clot. Heparin is given to individuals to lower their chance of developing blood clots if they have certain medical conditions or have certain medical procedures that enhance that risk. Heparin is able to stop blood clots from forming in blood vessels, but it cannot shrink the size of clots that have already been generated. Heparin is also used in low quantities to prevent blood clots from forming in catheters, which are tiny plastic tubes inserted into veins to collect blood or provide medication.

An injectable anticoagulant called heparin is frequently used during surgical procedures to stop blood clotting in the veins and arteries. In addition, it is utilized to treat conditions related to blood coagulation. In addition, it is used to identify and treat pulmonary, venous, and arterial thromboembolism. Unfractionated heparin is another name for heparin that is widely used. Heparin is a substance made from animal tissue that comes from butchered meat. The primary driver of the increase in heparin demand is the rise in accidents and surgical procedures. The need for heparin will also increase due to the prevalence of diseases, including cardiovascular illnesses. The market demand is also anticipated to be increased by spending to upgrade healthcare infrastructure and increase patient awareness.

Recent developments by key players in Heparin Market:

In January 2022- Optimvia Pharmaceuticals, an Ohio-based biotechnology company, claimed to have created a synthetic process for producing huge quantities of heparin, which is required to generate a common blood thinner at a reasonable rate.

Heparin is used clinically in deep vein thrombosis (DVT) therapy, dialysis, and most heart surgeries. Heparin also prevents blood clotting in open heart surgery, kidney dialysis, bypass surgery, and blood transfusions. With the global expansion of chronic renal disease, kidney dialysis procedures are rising. Heparin demand is also increasing due to an increase in surgeries and the incidence of diseases, including deep vein thrombosis and coronary heart disease, which will fuel the heparin market's growth throughout the forecast period. Moreover, there have been ongoing technological efforts to expand the applications of these products and present alternatives to goods generated from animals. However, the importance and criticality of this therapy during anticoagulation remain unaffected. The development and production of synthetic unfractionated heparin, LMWH, and ultralow mol weight heparin (ULMWH) have shown substantial promise in recent research efforts focusing on modulating enzymes related to the regulatory mechanisms of these drugs. The development of the synthetic form could lead to products with fewer Heparin-induced Thrombocytopenia (HIT) side effects and more clearly defined physical, chemical, biological, and pharmacological properties. Additionally, a few emerging businesses are collaborating to produce synthetic versions of these goods at a lower cost in order to replace those made from animal products. The creation of substitute materials and mergers among businesses are expected to boost this target market. However, heparin use can cause spontaneous bleeding in the stomach, intestines, ovaries, uterus, mouth, and gums, in addition to open wounds and surgical sites. A potentially fatal heparin side effect known as heparin-induced thrombocytopenia (HIT) happens when the medication causes the body to develop antibodies against its own platelets. This lowers platelet count and raises the risk of bleeding. The market is projected to constrain due to heparin's negative effects.

FutureWise Market Research has published a report that provides an insightful analysis of heparin market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the heparin market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Baxter
  • Leo Pharma A/S
  • Sanofi
  • Dr. Reddy’s Laboratories Ltd
  • Aspen Holdings
  • B. Braun Medical Inc.
  • Fresenius SE & Co. KGaA
  • Teva Pharmaceutical Industries Ltd
  • Bioiberica
  • Hebei Changshan Biochemical Pharmaceutical
  • Opocrin S.p.A
  • Laboratorios Farmaceuticos Rovi Sa
  • Syntex S.A

By Type

  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Unfractionated Heparin

By Route of Administration

  • Intravenous
  • Subcutaneous

By Application

  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Coronary Artery Disease
  • Others

By End User

  • Outpatient
  • Inpatient

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. APAC registered highest share in the market in 2022. The growth's main drivers are the increasing geriatric population, the large population with chronic diseases, and expanding economies. Additionally, Asia Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic versions of medications whose patents have expired are produced locally at a reasonable price, due to which the market is expected to grow in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Heparin Market By Type, By Route of administration, By Application, By End-user and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Route of Administrationology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Heparin Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Heparin Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Heparin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Heparin Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Low Molecular Weight Heparin
        2. Ultra-low Molecular Weight Heparin
        3. Unfractionated Heparin

  • 8.   Global Heparin Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravenous
        2. Subcutaneous

  • 9.   Global Heparin Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Venous Thromboembolism
        2. Atrial Fibrillation
        3. Renal Impairment
        4. Coronary Artery Disease
        5. Others

  • 10.   Global Heparin Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Outpatient
        2. Inpatient

  • 11.   North America Heparin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Heparin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Heparin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Heparin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)
    •   1. GlaxoSmithKline plc
         1.1. Company Overview
         1.2. Type Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer, Inc.
         2.1. Company Overview
         2.2. Type Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Baxter
         3.1. Company Overview
         3.2. Type Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Leo Pharma A/S
         4.1. Company Overview
         4.2. Type Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sanofi
         5.1. Company Overview
         5.2. Type Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Dr. Reddy’s Laboratories Ltd
         6.1. Company Overview
         6.2. Type Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Aspen Holdings
         7.1. Company Overview
         7.2. Type Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. B. Braun Medical Inc.
         8.1. Company Overview
         8.2. Type Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Fresenius SECo. KGaA
         9.1. Company Overview
         9.2. Type Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd.
         10.1. Company Overview
         10.2. Type Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Bioiberica
         11.1. Company Overview
         11.2. Technology Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Hebei Changshan Biochemical Pharmaceutical
         12.1. Company Overview
         12.2. Technology Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Opocrin S.p.A
         13.1. Company Overview
         13.2. Technology Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Laboratorios Farmaceuticos Rovi Sa
         14.1. Company Overview
         14.2. Technology Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Syntex S.A
         15.1. Company Overview
         15.2. Technology Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients